Clinical trial
2-Year Therapy With Teriparatide vs 1-yr Therapy Followed by 1-Year of…
NCT00191425 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00191425 |
|---|---|
| Title | 2-Year Therapy With Teriparatide vs 1-yr Therapy Followed by 1-Year of Raloxifene or Calcium/Vit D in Severe Postmenopausal Osteoporosis |
| Official title | Comparison of a 2-Year Therapy of Teriparatide Alone and Its Sequential Use for 1 Year, With or Without Raloxifene HCl, in the Treatment of Severe Postmenopausal Osteoporosis |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Osteoporosis, Postmenopausal |
| Intervention type | Drug |
| Interventions | Teriparatide, Raloxifene |
| Enrollment | 810 |
| Start date | Aug 1, 2002 |
| Completion | Nov 1, 2005 |
| First posted | Sep 19, 2005 |
| Last update posted | Jul 16, 2007 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: